A Phase 1/1b Study of IAM1363 in HER2 Cancers
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Iambic Therapeutics, Inc
- Target Recruit Count
- 287
- Registration Number
- NCT06253871
- Locations
- 🇺🇸
Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
© Copyright 2024. All Rights Reserved by MedPath